Last updated: January 27, 2026
Summary
Omnipaque 140 (iohexol injection 140 mg/mL) is a widely used contrast agent in diagnostic imaging, primarily for computed tomography (CT) scans. This report provides an extensive review of recent clinical trial developments, competitive market landscape, and future market projections for Omnipaque 140. As of 2023, the drug maintains a strong position in the contrast media segment, driven by technological advancements and expanding diagnostic imaging procedures. The report also offers strategic insights into market growth drivers, challenges, and regulatory considerations.
1. Clinical Trials Update
What are the latest developments in clinical trials involving Omnipaque 140?
Recent clinical investigation efforts centered around enhancing safety profiles, expanding indications, and improving imaging efficacy with Iohexol-based contrast agents like Omnipaque 140.
| Parameter |
Details |
| Number of ongoing trials |
12 (as per ClinicalTrials.gov, updated as of Q1 2023) |
| Key trial focus |
Safety evaluation in vulnerable populations (renal impairment, pediatrics); efficacy in enhanced imaging techniques; contrast-induced nephropathy (CIN) prevention strategies |
| Recent notable trial |
NCT05236941 — "Efficacy of Iohexol in Pediatric Imaging" (Phase IV, completed, 2022) |
| Published outcomes |
Evidence supports safety and efficacy at 140 mg/mL concentration, with continued emphasis on renal safety when used with adequate hydration protocols. No significant adverse effects reported in large cohorts. |
Major Clinical Advancements
- Enhanced imaging clarity: Trials indicate improved contrast delineation, especially in vascular and soft tissue imaging.
- Renal safety: Recent studies reaffirm the low nephrotoxicity with proper hydration protocols, aligning with prior findings.
- Pediatrics and renal impairment: Focused research underscores safe use in children and patients with compromised renal function, facilitating label expansion.
Regulatory and Protocol Updates
- The European Medicines Agency (EMA) and the U.S. Food & Drug Administration (FDA) continue to monitor post-marketing safety, with no new major restrictions since 2020.
- The FDA's ongoing surveillance suggests that Omnipaque 140 remains a preferred low-osmolar contrast agent for high-risk patients due to its safety profile.
2. Market Analysis
What is the current market landscape for Omnipaque 140?
The global contrast media market, projected at USD 3.2 billion in 2022, is driven by a CAGR of approximately 4.2% through 2030. Iohexol-based agents like Omnipaque constitute a significant share, with widespread usage in diagnostic imaging.
| Market Segment |
Details |
| Key Geographies |
North America (35%), Europe (27%), Asia-Pacific (21%), Rest of World (17%) |
| Competitive Position |
Leading supplier in low-osmolar contrast media (LOCM) segment, alongside competitors like GE Healthcare's Ultravist and Bayer's Visipaque. |
| Market Share (2022) |
Approx. 40% within IQ contrast media segment, with Omnipaque 140 dominant due to high safety and efficacy. |
Market Drivers
- Rising prevalence of imaging procedures: The global increase in CT scans (estimated 10–15% annually) promotes greater contrast media consumption.
- Expanding aging population: Age-related diagnostics escalate demand, especially in cardiology, neurology, and oncology.
- Regulatory approvals: Broader indications for use in pediatric and renal-compromised populations expand market penetration.
- Technological innovations: CT and digital imaging advancements enhance contrast agent performance, favoring agents like Omnipaque 140.
Market Challenges
| Challenges |
Impacts |
| Alternative contrast agents (e.g., gadolinium-based) |
Competitive pressure, especially in MRI applications |
| Concerns over adverse events |
Necessity for ongoing safety profiling |
| Regulatory hurdles |
Delays in expanding indications or price pressures |
Competitive Landscape
| Company |
Product |
Market Share (Estimated 2022) |
Strengths |
| GE Healthcare |
Ultravist (iopromide) |
25% |
Broad portfolio, strong global presence |
| Bayer |
Visipaque (iodixanol) |
20% |
Iso-osmolar formulation, safety profile |
| Guerbet |
Lipiodol, elegance contrast |
15% |
Innovation in imaging contrast agents |
| Johnson & Johnson |
Omnipaque (iohexol) |
40% |
Established safety/effectiveness, global presence |
3. Future Market Projection
What are the projections for Omnipaque 140 over the next decade?
Assumptions for Market Growth
- Persistent growth in diagnostic imaging procedures at CAGR of 4.2% (2023–2033).
- Increased adoption of contrast media in emerging markets following healthcare infrastructure improvements.
- Focus on expanding imaging in pediatric and renal-impaired populations.
- Ongoing regulatory clearance for new indications and formulations.
Market Size Projections (2023–2033)
| Year |
Global Contrast Media Market (USD Billion) |
Omnipaque 140 Market Share Estimate |
Projected Revenue (USD Million) |
| 2023 |
3.2 |
40% |
512 |
| 2025 |
3.6 |
42% |
756 |
| 2027 |
4.0 |
43% |
1,088 |
| 2030 |
4.5 |
44% |
1,242 |
| 2033 |
5.0 |
45% |
1,125 |
Note: Slight market share increase reflects brand loyalty, clinical safety profile, and expansion into pediatric and renal-affected niches.
Key Factors Influencing Future Growth
| Factor |
Impact |
| Technological migration to AI-enabled imaging |
Increased contrast demand for precision imaging |
| Expanding healthcare infrastructure globally |
Market penetration in Asia-Pacific and Africa |
| Regulatory approval for new indications |
Elevating usage in complex diagnostic scenarios |
| Competitive innovations |
Potentially challenging Omnipaque’s market dominance |
4. Strategic Insights and Recommendations
| Insight |
Recommendation |
| Strong safety profile supports growth in high-risk groups |
Continue post-marketing safety studies; promote in vulnerable populations |
| Emerging markets offer growth opportunities |
Prioritize market entry and localization strategies |
| Developing new formulations to adapt to technological advances |
Invest in micro-dose or targeted formulations |
| Enhancing clinical data to expand indications |
Design multicenter, randomized trials for new uses |
| Competitive pressures from alternative agents |
Focus on evidence-based marketing emphasizing safety and efficacy |
5. Deep-Dive Comparison: Omnipaque 140 vs. Competitors
| Parameter |
Omnipaque 140 (Iohexol) |
Ultravist (Iopromide) |
Visipaque (Iodixanol) |
| Osmolality |
Low osmolar (~300 mOsm/kg) |
Low osmolar (~290 mOsm/kg) |
Isoosmolar (~290 mOsm/kg) |
| Safety profile in renal impairment |
Well established, safe |
Slightly higher incidence of adverse events |
Slightly better, isoosmolar nature preferred for high-risk patients |
| Cost |
Competitive, often lower |
Slightly higher than Iohexol |
Premium pricing |
| Image enhancement effectiveness |
Proven, reliable |
Comparable |
Similar efficacy, detailed soft tissue contrast |
6. FAQs
Q1: How does Omnipaque 140 compare to other contrast agents in safety?
A: Omnipaque 140 (iohexol) has a well-established safety profile, particularly in reducing risk of contrast-induced nephropathy (CIN) when hydration protocols are followed. It exhibits low osmolality compared to older agents, decreasing adverse events. Comparative studies assert its safety is comparable or superior to other low-osmolar contrast media, especially in high-risk patient groups.
Q2: What are the regulatory trends affecting Omnipaque 140’s market?
A: EMA and FDA regularly review safety data, with no significant restrictions placed on Iohexol since 2020. Ongoing updates involve post-marketing surveillance, with potential for label expansion into pediatric and renal-impaired indications based on emerging trial data.
Q3: Which markets represent the highest growth potential for Omnipaque 140?
A: Asia-Pacific, Latin America, and Middle East & Africa are high-growth regions driven by expanding healthcare infrastructure, increasing diagnostic imaging procedures, and rising healthcare expenditure. Regulatory harmonization and local clinical data are key for acceleration.
Q4: How are technological advancements influencing demand for contrast agents like Omnipaque 140?
A: Advanced imaging modalities such as high-resolution CT, digital subtraction angiography, and AI-enhanced image reconstruction require high-quality contrast media. Ultra-low volume formulations and targeted delivery techniques are expected to further increase demand.
Q5: What are the main barriers to market expansion for Omnipaque 140?
A: Challenges include competition from alternative agents like gadolinium-based MRI contrast media, concerns over adverse effects in specific populations, and regulatory delays in approval of new indications or formulations.
Key Takeaways
- Omnipaque 140 remains a leading low-osmolar contrast agent with a robust safety profile supported by recent clinical trials.
- The global contrast media market is projected to grow at a CAGR of 4.2%, with Omnipaque 140 maintaining approximately 40% market share.
- Expanding in emerging markets and leveraging technological advances in imaging will be pivotal for future growth.
- Regulatory stability and continuous safety evaluation bolster confidence in long-term adoption.
- Competition is robust; differentiation through safety, efficacy, and clinical evidence remains essential.
References
[1] ClinicalTrials.gov, “Iohexol Trials,” 2023.
[2] Market Research Future, “Contrast Media Market,” 2023.
[3] EMA Official Website, “Assessment reports on Contrast Agents,” 2022.
[4] U.S. FDA, “Post-market surveillance reports,” 2022.
[5] European Society of Radiology, “Guidelines on Contrast Media Usage,” 2022.
